Group items tagged

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.

Applicants must choose one of the following categories they feel their project best exemplifies: 1.) Outstanding Emerging Innovation: The winning nominee is a person or company working on the basic research phase of an innovation - for three years or less, pre-commercialization - that has received grant money or outside money and that demonstrates the potential for continued growth and success. 2.) Outstanding Bioscience Innovation: The winning nominee is a company that has achieved a significant milestone in the life sciences, including but not limited to drug therapeutics, medical devices, medical imaging and pharmacogenetics. 3.) Outstanding Information Technology Innovation: The winning nominee is a company that has achieved a significant milestone in information technology, including hardware and software, packaged applications, custom applications and digital media. 4.) Outstanding Marketing Innovation: The winning nominee is a company that has achieved a significant milestone in consumer marketing. 5.) Outstanding Advanced Engineering Innovation: The winning nominee is a company that has achieved a significant milestone in advanced engineering - where technology is used to design a product.

The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer. Because the intent of the Innovator Award mechanism is to recognize these remarkably creative and innovative, visionary individuals rather than projects, the central feature of the award is the innovative contribution that the Principal Investigator (PI) can make toward ending breast cancer.

To support highly innovative, high-risk, high-reward research that could ultimately lead to critical discoveries or major advancements that will accelerate the field of cardiovascular and stroke research. Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities.  The Innovative Research Grant (IRG) promotes new ideas; therefore, proposals need not include preliminary data.  However, a solid rationale for the work must be provided.  Proposed work should not be the next logical step of previous work, but should have a high probability of revealing new avenues of investigation, if successful.  This program aims to provide pilot or seed funding that should lead to successful competition for additional funding beyond the pilot period. The principal investigator (PI) is responsible for clearly and explicitly articulating the project's innovation and the potential impact on cardiovascular and stroke research.

Alex's Lemonade Stand Foundation (ALSF) is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. Innovation grants are designed as seed funding for researchers with a novel approach to pediatric oncology scientific investigation. This may represent a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications and evidence of successfully competing for extramural funding. The grant is for two years up to $125,000 per year. A one year no cost extension is encouraged.

Olfaction is an evolutionarily primitive sense critical for survival across the animal kingdom - finding food, searching for mates, or avoiding predation all depend on detecting, identifying, and discriminating odors. Although early steps in olfactory processing are relatively well understood, significant gaps remain in our understanding of higher-order odor representations and processing during on-going behavior. Deciphering the operating principles of olfaction requires the development of innovative and integrative approaches that combine novel theoretical frameworks, improved mathematical models, and novel behavioral paradigms across the phylogenetic spectrum, experimental methodologies, and engineering principles. This solicitation describes an Ideas Lab on "Cracking the Olfactory Code." Ideas Labs are intensive workshops focused on finding innovative solutions to grand challenge problems. The ultimate aim of this Ideas Lab organized by the Biological Sciences (BIO) and the Mathematical and Physical Sciences (MPS) Directorates at the National Science Foundation (NSF) is to facilitate the generation and execution of innovative research projects aimed at understanding the nature of olfactory processing and sensory representations in the brain in general. The aspiration is that mixing researchers from diverse scientific backgrounds will engender fresh thinking and innovative approaches that will transform our understanding of olfactory processing in behavioral contexts while spawning new opportunities to elucidate the general nature of sensory representations in the brain. This multi-directorate program is one element of NSF's multi-year effort towards the goals of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative (http://www.nsf.gov/brain/). US researchers may submit preliminary proposals only via FastLane for participation in the Ideas Lab in which a set of multidisciplinary ideas

The Exploration - Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field. The studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is not required. The proposed research project should be innovative. Innovative research may examine a novel paradigm, challenge current paradigms, look at existing problems from novel perspectives, or exhibit other highly creative qualities. Research that is an incremental advance beyond ongoing research and published data is not considered innovative and is not consistent with the intent of this award mechanism. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research project is innovative in the field of MS research.

The Exploration - Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the multiple sclerosis research field. The studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is not required. The proposed research project should be innovative. Innovative research may examine a novel paradigm, challenge current paradigms, look at existing problems from novel perspectives, or exhibit other highly creative qualities. Research that is an incremental advance beyond ongoing research and published data is not considered innovative and is not consistent with the intent of this award mechanism. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research project is innovative in the field of multiple sclerosis research.

VentureWell, with the support from the Whitaker International Program, is implementing a new grants program, BME-IDEA International: Developing Global Connections for US-based BME Design Faculty and Students. The BME-IDEA International grants program will support collaborative project opportunities for US-based BME design students and faculty across the BME-IDEA global network and will connect faculty members of the consortium to share resources, best practices, ideas, curriculum, knowledge, challenges, and opportunities around innovation in BME design. The two goals of the BME-IDEA International grants program are to: 1) Build strong partnerships between US-based and global BME design and innovation programs, including exchanges of faculty, students, resources, and best practices. 2) Foster the development of US-trained leaders in BME design and innovation who understand the challenges of teaching and practice in this field around the world, especially in low- and middle-income countries (LMIC) in Africa and Latin America. Faculty Grants: Grants of up to $4,000 will be awarded to US-based faculty for global project explorations and/or experiences to enhance their professional development and knowledge base within the field of biomedical design and innovation.  Student Grants: Grants of up to $9,000 will be awarded to student teams for the development and implementation of BME projects focused on innovation, design, and entrepreneurship.

Alex's Lemonade Stand Foundation, a nonprofit foundation that has evolved from a young cancer patient's front-yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical voids in current pediatric cancer research. Through its Innovation Grants program, the foundation awards two-year grants of up to $250,000 to researchers with a novel approach to pediatric oncology scientific investigation. That can include a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications, and can demonstrate evidence of having successfully competed for extramural funding.

Alex's Lemonade Stand Foundation, a nonprofit foundation that has evolved from a young cancer patient's front-yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical voids in current pediatric cancer research. Through its Innovation Grants program, the foundation awards two-year grants of up to $250,000 to researchers with a novel approach to pediatric oncology scientific investigation. That can include a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications, and can demonstrate evidence of having successfully competed for extramural funding.

The Science of Science & Innovation Policy (SciSIP) program supports research designed to advance the scientific basis of science and innovation policy. Research funded by the program thus develops, improves and expands models, analytical tools, data and metrics that can be applied in the science policy decision making process. For example, research proposals may develop behavioral and analytical conceptualizations, frameworks or models that have applications across a broad array of SciSIP challenges, including the relationship between broader participation and innovation or creativity. Proposals may also develop methodologies to analyze science and technology data, and to convey the information to a variety of audiences. Researchers are also encouraged to create or improve science and engineering data, metrics and indicators reflecting current discovery, particularly proposals that demonstrate the viability of collecting and analyzing data on knowledge generation and innovation in organizations. Among the many research topics supported are:examinations of the ways in which the contexts, structures and processes of science and engineering research are affected by policy decision, the evaluation of the tangible and intangible returns from investments in science and from investments in research and development, the study of structures and processes that facilitate the development of usable knowledge, theories of creative processes and their transformation into social and economic outcomes, the collection, analysis and visualization of new data describing the scientific and engineering enterprise. The SciSIP program invites the participation of researchers from all of the social, behavioral and economic sciences as well as those working in domain-specific applications such as chemistry, biology, physics, or nanotechnology. The program welcomes proposals for individual or multi-investigator research projects, doctoral dissertation improvement awards, conferences, wo

The purpose of the administrative supplement is to provide support for NIH-funded investigators to participate in an entrepreneurship training course, the Concept to Clinic: Commercializing Innovation (C3i) Program. The C3i Program is designed to provide medical device innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic). Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their innovation. Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about the program before applying.

The purpose of the administrative supplement is to provide support for NIH-funded investigators to participate in an entrepreneurship training course, the Concept to Clinic: Commercializing Innovation (C3i) Program. The C3i Program is designed to provide medical device innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic). Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their innovation. Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about the program before applying.

The NIH Directors New Innovator Award supports early stage investigators of exceptional creativity who propose highly innovative new research approaches with the potential to produce a major impact on broad, important problems in biomedical or behavioral research. Applications from individuals with diverse backgrounds and in any topic relevant to the broad mission of NIH are welcome. The NIH Director's New Innovator Award complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators. The NIH Directors New Innovator Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.

The OCRP Teal Innovator Award supports a visionary individual from any field principally outside of, but not exclusive of, ovarian cancer to focus his/her creativity, innovation, and leadership on ovarian cancer research. The Teal Innovator Award will provide the Principal Investigator (PI) with the funding and freedom to pursue his/her most novel, visionary, high-risk ideas that could significantly impact the field of ovarian cancer research or patient care. The proposed Teal Innovator must be highly recognized in his/her field and present evidence of this recognition. Examples include, but are not limited to, recognition at the level of endowed chair; membership in the National Academy of Sciences, National Academy of Engineering, or Institute of Medicine; Chairmanship of the American Association for Cancer Research; or other national or international recognition.

The NIH Directors New Innovator (DP2) Award initiative supports a small number of early stage investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on broad, important problems in biomedical and behavioral research. The New Innovator Award initiative complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators. The NIH Directors New Innovator Award initiative is a component of the High Risk - High Reward Research Program of the NIH Common Fund.

The BIGDATA program seeks novel approaches in computer science, statistics, computational science, and mathematics, along with innovative applications in domain science, including social and behavioral sciences, geosciences, education, biology, the physical sciences, and engineering that lead towards the further development of the interdisciplinary field of data science. The solicitation invites two types of proposals: "Foundations" (F): those developing or studying fundamental theories, techniques, methodologies, technologies of broad applicability to Big Data problems; and "Innovative Applications" (IA): those developing techniques, methodologies and technologies of key importance to a Big Data problem directly impacting at least one specific application. Therefore, projects in this category must be collaborative, involving researchers from domain disciplines and one or more methodological disciplines, e.g., computer science, statistics, mathematics, simulation and modeling, etc. While Innovative Applications (IA) proposals may address critical big data challenges within a specific domain, a high level of innovation is expected in all proposals and proposals should, in general, strive to provide solutions with potential for a broader impact on data science and its applications. IA proposals may focus on novel theoretical analysis and/or on experimental evaluation of techniques and methodologies within a specific domain. Proposals in all areas of sciences and engineering covered by participating directorates at NSF are welcome.

Olfaction is an evolutionarily primitive sense critical for survival across the animal kingdom - finding food, searching for mates, or avoiding predation all depend on detecting, identifying, and discriminating odors. Although early steps in olfactory processing are relatively well understood, significant gaps remain in our understanding of higher-order odor representations and processing during on-going behavior. Deciphering the operating principles of olfaction requires the development of innovative and integrative approaches that combine novel theoretical frameworks, improved mathematical models, and novel behavioral paradigms across the phylogenetic spectrum, experimental methodologies, and engineering principles. This solicitation describes an Ideas Lab on "Cracking the Olfactory Code." Ideas Labs are intensive workshops focused on finding innovative solutions to grand challenge problems. The ultimate aim of this Ideas Lab organized by the Biological Sciences (BIO) and the Mathematical and Physical Sciences (MPS) Directorates at the National Science Foundation (NSF) is to facilitate the generation and execution of innovative research projects aimed at understanding the nature of olfactory processing and sensory representations in the brain in general. The aspiration is that mixing researchers from diverse scientific backgrounds will engender fresh thinking and innovative approaches that will transform our understanding of olfactory processing in behavioral contexts while spawning new opportunities to elucidate the general nature of sensory representations in the brain.

The Idea Development Award promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale. The following are important aspects of the Idea Development Award: * Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care. * Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (the next logical step) is not considered innovative. * Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI)

We encourage applications from innovators working in all aspects of pediatric oncology, pediatric surgical care, and influenza. Specific areas of focus include: Pediatric Oncology -Innovations in pediatric oncology port technologies -Drugs that target pediatric-specific driver genes -Bedside, rapid tumor genetic testing Pediatric Surgical Care -Pediatric-specific implants for trauma & fracture care including growth-enabling spine & trauma orthopedic implants -Innovative treatment options for adolescent idiopathic scoliosis -Surgical robotics to treat pediatric patients Influenza -Pediatric-focused innovations in influenza -Novel solutions for influenza vaccine delivery -Influenza pre-exposure including antivirals prophylaxis formulation Applications will be accepted across: -Pharmaceuticals -Medical devices -Consumer products -Global public health -Health technologies -Cross-sector initiatives (an integration of one or more areas of focus mentioned above) Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria: -Potential impact -Uniqueness of solution & level of competition in the current market -Quality & feasibility of the technology -Team credibility & capabilities -Plans for utilizing JLABS @ Washington, DC